Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD

      Objective

      Patients with COPD are at risk for cardiovascular events. This is attributed to increased systemic inflammation. The course of COPD is punctuated by exacerbations, which further increase systemic inflammation, but the risk of vascular events in the postexacerbation period has never been defined.

      Methods

      We analyzed data from 25,857 patients with COPD entered in The Health Improvement Network database over a 2-year period. Exacerbations were defined using a health-care use definition of prescription of oral corticosteroids > 20 mg/d and/or selected oral antibiotics. The risk of myocardial infarction (MI) and stroke in the postexacerbation period was calculated relative to the patient's baseline risk using the self-controlled case series approach.

      Results

      We identified 524 MIs in 426 patients and 633 ischemic strokes in 482 patients. The incidence rates of MI and stroke were 1.1 and 1.4 per 100 patient-years, respectively. There was a 2.27-fold (95% CI, 1.1–4.7; P = .03) increased risk of MI 1 to 5 days after exacerbation (defined by prescription of both steroids and antibiotics). This relative risk diminished progressively with time and was not significantly different from the baseline MI risk at any other postexacerbation time interval. One in 2,513 exacerbations was associated with MI within 1 to 5 days. There was a 1.26-fold (95% CI, 1.0–1.6; P = .05) increased risk of stroke 1 to 49 days after exacerbation.

      Conclusion

      The results suggest that exacerbations of COPD increase the risk of MI and stroke. This may have implications for therapy in both stable and exacerbated COPD.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Murray CJ
        • Lopez AD
        Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.
        Lancet. 1997; 349: 1498-1504
        • Man SF
        • Connett JE
        • Anthonisen NR
        • Wise RA
        • Tashkin DP
        • Sin DD
        C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.
        Thorax. 2006; 61: 849-853
        • Camilli AE
        • Robbins DR
        • Lebowitz MD
        Death certificate reporting of confirmed airways obstructive disease.
        Am J Epidemiol. 1991; 133: 795-800
        • Anthonisen NR
        • Connett JE
        • Enright PL
        • Manfreda J
        • Lung Health Study Research Group
        Hospitalizations and mortality in the Lung Health Study.
        Am J Respir Crit Care Med. 2002; 166: 333-339
        • Sin DD
        • Anthonisen NR
        • Soriano JB
        • Agusti AG
        Mortality in COPD: role of comorbidities.
        Eur Respir J. 2006; 28: 1245-1257
        • Calverley PM
        • Anderson JA
        • Celli B
        • TORCH investigators
        • et al.
        Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
        N Engl J Med. 2007; 356: 775-789
        • Donaldson GC
        • Seemungal TAR
        • Bhowmik A
        • Wedzicha JA
        Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
        Thorax. 2002; 57: 847-852
        • Seemungal TA
        • Donaldson GC
        • Paul EA
        • Bestall JC
        • Jeffries DJ
        • Wedzicha JA
        Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 1998; 157: 1418-1422
        • Donaldson GC
        • Wilkinson TM
        • Hurst JR
        • Perera WR
        • Wedzicha JA
        Exacerbations and time spent outdoors in chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2005; 171: 446-452
        • Bhowmik A
        • Seemungal TA
        • Sapsford RJ
        • Wedzicha JA
        Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.
        Thorax. 2000; 55: 114-120
        • Donaldson GC
        • Seemungal TA
        • Patel IS
        • et al.
        Airway and systemic inflammation and decline in lung function in patients with chronic obstructive pulmonary disease.
        Chest. 2005; 128: 1995-2004
        • Soler-Cataluña JJ
        • Martínez-García MÁ
        • Román Sánchez P
        • Salcedo E
        • Navarro M
        • Ochando R
        Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.
        Thorax. 2005; 60: 925-931
        • Seemungal TA
        • Harper-Owen R
        • Bhowmik A
        • Jeffries DJ
        • Wedzicha JA
        Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease.
        Eur Respir J. 2000; 16: 677-683
        • Seemungal T
        • Harper-Owen R
        • Bhowmik A
        • et al.
        Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2001; 164: 1618-1623
        • Wedzicha JA
        • Seemungal TAR
        • MacCallum PK
        • et al.
        Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels.
        Thromb Haemost. 2000; 84: 210-215
        • Danesh J
        • Collins R
        • Appleby P
        • Peto R
        Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.
        JAMA. 1998; 279: 1477-1482
        • Fisman EZ
        • Benderly M
        • Esper RJ
        • et al.
        Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction.
        Am J Cardiol. 2006; 98: 14-18
        • Dahl M
        • Vestbo J
        • Lange P
        • Bojesen SE
        • Tybjærg-Hansen A
        • Nordestgaard BG
        C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2007; 175: 250-255
        • Smeeth L
        • Thomas SL
        • Hall AJ
        • Hubbard R
        • Farrington P
        • Vallance P
        Risk of myocardial infarction and stroke after acute infection or vaccination.
        N Engl J Med. 2004; 351: 2611-2618
        • Meier CR
        • Jick SS
        • Derby LE
        • Vasilakis C
        • Jick H
        Acute respiratory-tract infections and risk of first-time acute myocardial infarction.
        Lancet. 1998; 351: 1467-1471
        • Lewis JD
        • Schinnar R
        • Bilker WB
        • Wang X
        • Strom BL
        Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
        Pharmacoepidemiol Drug Saf. 2007; 16: 393-401
        • Smith CJP
        • Gribbin J
        • Challen KB
        • Hubbard RB
        The impact of the 2004 NICE guideline and 2003 General Medical Services contract on COPD in primary care in the UK.
        QJM. 2008; 101: 145-153
        • Whitaker HJ
        • Farrington CP
        • Spiessens B
        • Musonda P
        Tutorial in biostatistics: the self-controlled case series method.
        Stat Med. 2006; 25: 1768-1797
        • Jick H
        • Terris BZ
        • Derby LE
        • Jick SS
        Further validation of information recorded on general practitioner based computerised data resources in the United Kingdom.
        Pharmacoepidemiol Drug Saf. 1992; 1: 347-349
        • Hollowell J
        The General Practice Research Database: quality of morbidity data.
        Popul Trends. 1997; 87: 36-40
        • Soedamah-Muthu SS
        • Fuller JH
        • Mulnier HE
        • Raleigh VS
        • Lawrenson RA
        • Colhoun HM
        High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database.
        Diabetes Care. 2006; 29: 798-804
        • Donaldson GC
        • Seemungal T
        • Jeffries DJ
        • Wedzicha JA
        Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease.
        Eur Respir J. 1999; 13: 844-849
        • von Elm E
        • Altman DG
        • Egger M
        • Pocock SJ
        • Gøtzsche PC
        • Vandenbroucke JP
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.
        Prev Med. 2007; 45: 247-251
        • Fabbri LM
        • Rabe KF
        From COPD to chronic systemic inflammatory syndrome?.
        Lancet. 2007; 370: 797-799
        • Hurst JR
        • Donaldson GC
        • Perera WR
        • et al.
        Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2006; 174: 867-874
        • Meade TW
        • Ruddock V
        • Stirling Y
        • Chakrabarti R
        • Miller GJ
        Fibrinolytic activity, clotting factors and long term incidence of ischaemic heart disease in the Northwick Park Heart Study.
        Lancet. 1993; 342: 1076-1079
        • Salpeter SR
        • Ormiston TM
        • Salpeter EE
        Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis.
        Chest. 2004; 125: 2309-2321
        • Wilkinson TM
        • Donaldson GC
        • Hurst JR
        • Seemungal TA
        • Wedzicha JA
        Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease.
        Am J Respir Crit Care Med. 2004; 169: 1298-1303
        • Maxwell SR
        • Moots RJ
        • Kendall MJ
        Corticosteroids: do they damage the cardiovascular system?.
        Postgrad Med J. 1994; 70: 863-870
        • Clayton TC
        • Thompson M
        • Meade TW
        Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database.
        Eur Heart J. 2008; 29: 96-103